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Objective: Off-pump valve replacement using self-expandable stents is an emerging technique for pulmonary
valve disease. However, significant limitations are the lack of easily available valve substitute to be inserted
within the stent and, in the setting of repaired tetralogy of Fallot, the existence of huge pulmonary trunk. We report
the first experimental results of a transventricular approach using a decellularized porcine xenograft mounted in
a self-expandable stent.
Methods: Pulmonary valve replacement was realized in 15 lambs by direct access of the infundibulum through
a left thoracotomy, combined with pulmonary artery banding. Animals were followed by transthoracic echocar-
diography and, after control hemodynamic study, were electively killed either at day 7, month 1, or month 4 after
implantation.
Results: Implantation succeeded in all lambs. Two animals died after implantation (1 pneumothorax and 1 en-
docarditis). Doppler echocardiographic follow-up did not show any significant transvalvular gradient and showed
only mild pulmonary regurgitation. The hemodynamic control before termination revealed a systolic pulmonary
valve gradient of 18.5  12.4 mm Hg at 1 week (n ¼ 4), 13.5  10.6 mm Hg at 1 month (n ¼ 4), and 4.3  4.9
mm Hg at 4 months (n ¼ 5). Gross examination demonstrated the presence of connective tissue between the
valved stent and pulmonary wall, which increased with time.
Conclusion: Fifteen lambs underwent successful deployment of a self-expandable valved stent in the pulmonary
position using a transventricular approach. This technique combined with pulmonary artery banding could be
a therapeutic option for pulmonary insufficiency after repair of tetralogy of Fallot with a transannular patch.
Godart et al Congenital Heart DiseaseIn patients with congenital heart disease who had surgical
pulmonary valvectomy or transannular pulmonary patch,
the pulmonary regurgitation can lead to severe right ventric-
ular failure. The classical surgical repair under cardiopulmo-
nary bypass remains the first-line treatment to replace the
pulmonary valve but may in fact deteriorate the right ventric-
ular function.1 More recently, different alternatives have
been proposed such as percutaneous implantation or trans-
ventricular approach.2-6 This latter is obviously more inva-
sive for the patient than the transvenous insertion but
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a cardiopulmonary bypass and is not limited to reduced
valve diameter by small catheters or vessel dimensions. Us-
ing such an approach, the first implantations in humans were
reported by Berdat and Carrel5 with a porcine pulmonic
valve mounted on a self-expandable stent, and then later
by a German team.6 The reported results were very promis-
ing, but both groups experienced significant drawbacks such
as paravalvular leakage and valve migration requiring fur-
ther surgery. We report here our results of an experimental
study of an off-pump pulmonary valve implantation without
cardiopulmonary bypass, through a transventricular ap-
proach using a decellularized porcine xenograft mounted
in a self-expandable stent, and combined with pulmonary
artery reduction.
MATERIAL AND METHODS
All animals received humane care in accordance with the ‘‘Principles of
Laboratory Animal Care’’ and the ‘‘Guide for the Care and Use of Laboratory
Animals’’ (National Institutes of Health publication No. 85-23, revised 1985).
Preparation of the Valve
The selected valve was a decellularized porcine xenograft, prepared in
our laboratory as previously described from female piglets (Large White/
Landras, 20–25 kg body weight).7 The procedure was performed after me-
dian sternotomy under surgical conditions. Porcine pulmonic root tissue
was obtained from fresh dissection and a blade-cleaning procedure to
remove excess connective tissue and myocardium, leaving a thin ridge ofardiovascular Surgery c Volume 137, Number 5 1141




RVOT ¼ right ventricular outflow tract
subvalvular muscle tissue proximally and a short arterial segment distally
(Figure 1, A). The porcine valve conduits were then calibrated with a Hegar
dilator. The classical preparation using glutaraldehyde was replaced here by
techniques of hypotonic nonenzymatic solutions.7-9 This decellularized
xenograft has been demonstrated to sustain physiologic shear stress.7
Preparation of the Valved Stent and Delivery System
A self-expandable stent made of nitinol, which is a memory-shape alloy
(Bard Luminexx; Angiomed GmbH, Karlsruhe, Germany), was employed
(30 mm in length and 18 mm in diameter). On the same day of implantation,
the porcine valve described above was sewed distally and proximally by
running suture in the stent (Figure 1, B). To avoid hammock aspect of the
valve, additional sutures were realized in the middle part of the valved stent
on 4 cardinal points, and the valve was immersed in saline solution until the
implantation (Figure 1, C). The delivery system consisted of a front-loading
22/24-French sheath with outer diameter constant on all its length (Gore In-
troducer Sheath, Gore and Associates, Flagstaff, Ariz). The inner dilator was
distally modified to receive the valved stent within the sheath. It had also a 2-
cm conical-shaped tip to allow smooth transition between the tip and the
sheath, thus limiting the risk of trauma of ventricle or vessel wall at implan-
tation. The valved stent was loaded by hand-crimping into the previously
described delivery system just before release to minimize time of valve com-
pression within the sheath.
Technique of Valve Placement
Valved stents were implanted in lambs (Romanov/Ile de France, 22–34
kg body weight). Animals were placed in right lateral position. In each case,
a catheter was placed in the jugular vein to gain access for delivery of med-
ication and a second one in a small artery on the ear to monitor the blood
pressure. General anesthesia was induced by means of intravenous injection
of propofol (500 mg kg1 min1) and sufentanil (0.5 mg/kg body weight)
followed by a continuous venous injection of propofol (500 mg kg1
min1) and sufentanil (1 mg kg1 h1). Lambs were intubated and mechani-
cally ventilated. Cardiac and respiratory functions were monitored during
the entire procedure. Systemic anticoagulation was induced with heparin1142 The Journal of Thoracic and Cardiovascular Su(300 UI/kg). All animals received xylocaine (1 mg/kg) to prevent ventricu-
lar arrhythmia and were perfused with isotonic saline solution.
A thoracotomy was performed through the fourth left intercostal space.
The main pulmonary artery was first dissected free to allow placement of
a band around the trunk. The band was tightened to reduce the diameter
just below 18 mm and avoid distal embolization of the valved stent in pul-
monary vasculature. Then to correctly visualize the pulmonary annulus at
implantation, 2 radiopaque markers were placed on the pulmonary artery
trunk: the first at the level of the annulus and the second at the distal
band. The site of puncture on the right ventricular outflow tract (RVOT)
was secured by a purse using a 3-0 polypropylene filament and 2 Teflon felts
separated by 15 mm. The right ventricular infundibulum was punctured
about 2 cm beneath the pulmonary annulus in the direction of the pulmonary
trunk by a 16-gauge needle. A 0.035-inch guide wire was advanced in the
lumen of needle and the left pulmonary artery, and the needle was replaced
by a 6-French Radifocus Introducer II (Terumo Corporation, Tokyo, Japan).
Under fluoroscopic guidance, the initial guide wire was exchanged for
a 260-cm-long 0.035-inch Rosen curved guide wire (Cook; William Cook
Europe, Bjaeverskov, Denmark) placed in the distal left pulmonary artery.
The large introducing sheath with the valved stent was then advanced
over that wire and pushed gently with rotational movements to cross the in-
fundibular wall into the RVOT (Figure 2). After correct positioning con-
trolled by fluoroscopic guidance, the valved stent was ejected from the
sheath by keeping the inner dilator fixed while the outer sheath was slowly
withdrawn, allowing immediate deployment of the valved stent. Bleeding
was controlled by tightening of the purse string. Assessment of the valve
performance was performed by echocardiography using epicardial scanning
with a transducer wrapped in a sterile sleeve. Following the procedure, the
ventriculotomy was closed with the suture of the purse and chest in layers by
using resorbable sutures. After extubation, animals were settled in standard
conditions, with food and drink ad libitum. All animals received 1000 mg of
ceftriaxon and 500 mg of aspirin for the first postoperative week on a daily
basis. For pain control, a transdermal fentanyl patch was applied for the first
2 days after implantation.
Follow-up Protocol
Animals were evaluated by routine Doppler echocardiographic fol-
low-up after 7 days, 1 month, and 4 months using Vingmed CFM
800 with a 5-MHz probe. Evaluation criteria were: peak systolic gradi-
ent across the valved stent and pulmonary valve competence analyzed
by color Doppler mapping and graded as mild, moderate, and severe.
Euthanasia was performed under the same protocol of analgesia and
anesthetic procedures as for implantation. Before death at day 7, 1FIGURE 1. Gross appearance of the valved stent. A, Only a thin ridge of subvalvular muscle tissue remains proximally within the stent. B, The porcine
xenograft valve is sewed distally and proximally by a running suture on the self-expandable stent. Notice the normal tricuspid aspect of the valve and its
competence. C, Additional sutures are realized in the middle part of the valved stent on 4 cardinal points to avoid hammock aspect.rgery c May 2009
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cardiac catheterization with hemodynamic calculations and angiography
was performed to detect valved stent abnormalities and to measure
transvalvular gradient.
RESULTS
Valve insertion was attempted in 15 lambs and succeeded
in all. The overall procedure times was 100 minutes, but du-
ration from puncture of RVOT, delivery, and valve deploy-
ment to infundibular closure was less than 10 minutes. After
release, valves were deployed in RVOT in less than 5 sec-
onds. All animals survived the operative procedure. One
died the day after from a pneumothorax but postmortem ex-
amination revealed a functional pulmonary valve. Another
died 3 weeks after implantation from endocarditis leading
to severe obstruction of the valved stent.
Functionally, Doppler echocardiography demonstrated
good valvular function in the remaining animals without sig-
nificant regurgitation or stenosis with time. Detailed results
FIGURE 2. The large introducer system with the valved stent is advanced
and pushed gently with rotational movements to cross the infundibular wall
into the right ventricular outflow tract. It has a 2-cm conical-shaped tip to
allow smooth transition between the tip and the sheath to avoid trauma at
implantation. PAT, Pulmonary artery trunk; INTR, 22/24 F introducer.
FIGURE 3. Pulmonary transvalvular systolic gradient by Doppler echo-
cardiography at day 7 and 1 and 4 months after implantation. D, Day; M,
month.The Journal of Thoracic and Cof systolic pulmonary valve gradient are reported in Figure 3.
Mild pulmonary regurgitation was noticed in 1 lamb at day
7, in 2 lambs at month 1, and in 1 lamb at month 4 after
implantation. In addition, 4 lambs exhibited a small para-
prosthetic leak at the 1 week.
Four animals were sacrificed at day 7, 4 at 1 month, and 5
at 4 months. Control cardiac catheterization performed just
before sacrifice displayed a systolic pulmonary valve
gradient of 18.5  12.4 mm Hg (range 2.0–29.0 mm Hg)
at day 7, 13.5  10.6 mm Hg (range 4.0–25.0 mm Hg) at
1 month, and 4.3  4.9 mm Hg (range 1–10 mm Hg) at 4
months. Following sacrifice, gross anatomic examination
demonstrated connective tissue between the valved stent
and pulmonary wall, which increased with time: none in
the 4 lambs at day 7, proximally in 1 of the 4 lambs at 1
month, and both proximally and distally in all 5 lambs sac-
rificed at 4 months (Figure 4). Valve morphology was nor-
mal with functional competence in all animals but 2. In
these 2 animals killed at 4 months, valves exhibited a restric-
tive mobility due to small leaflet retraction leading to insig-
nificant obstruction or regurgitation (as shown by the
echocardiographic study).
DISCUSSION
In congenital heart disease, pulmonary valve replacement
is frequently needed. The most frequent reason is pulmonary
valve incompetence following repaired tetralogy of Fallot
with the transannular patch technique, which is realized in
up to 70% of patients. The consequence is a pulmonary
regurgitation leading to right ventricular volume overload,
dilatation, and possible severe right ventricular dysfunction,
leading to significant late morbidity and mortality.10 In addi-
tion, the transannular patch induces frequent dilatation and/
or aneurysm of the main pulmonary artery. In this work, we
FIGURE 4. Macroscopic examination after fixation in paraformaldehyde
solution showing persistent thin aspect of the pulmonary valve leaflet, 4
months after implantation.ardiovascular Surgery c Volume 137, Number 5 1143
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replacement. Innovative surgical techniques are usually
less invasive and tend to improve patient outcome, length
of hospital stay, and perioperative mortality and morbidity.
The most often described innovative approach is the per-
cutaneous pulmonary valve replacement as reported by Bon-
hoeffer, with the Melody Transcatheter Pulmonary Valve
(Medtronic Inc, Minneapolis, Minn).3 However, this tech-
nique is actually limited to calcified pulmonary prosthetic
conduit not exceeding 22-mm diameter and mainly re-
stricted to adolescents and adults.11 In fact, such procedure
is not the answer for patients with repaired tetralogy of Fallot
by transannular patch who clearly have a dilated or even
aneurysmal pulmonary artery requiring a larger-diameter
device.
The transventricular approach clearly has some advan-
tages. First, it decreases distance to the target site and pro-
vides the ability to deliver a large introducing system
without cardiopulmonary bypass.12 Second, it is not limited
by a possible ‘‘size mismatch’’ between access vessel and
delivery system. Third, it allows off-pump pulmonary valve
replacement. A transventricular approach was first used by
Berdat and Carrel5 in 4 children, using a Shelhigh injectable
porcine pulmonic valve mounted in a self-expandable stent.
This technique, very similar to that reported here, was suc-
cessful for valve delivery and placement, but 1 child re-
quired reoperation 2 months later due to valve migration
with severe pulmonary artery obstruction. A similar tech-
nique of implantation has been more recently reported
with success in 6 patients, but once again, 1 patient with
huge RVOT required homograft insertion 2 days later due
to significant paravalvular leak.6 In our experience, we
resolved these limitations by first reducing the diameter of
the main pulmonary artery with a band to decrease the risk
of valved stent migration in the pulmonary vasculature.
Valve embolization could also be anticipated by securing
valve position by several additional transmural sutures at
the proximal and distal rim of the valved stent during im-
plantation.13,14 In fact, the transventricular approach appears
to be a real alternative for patients with repaired tetralogy of
Fallot and huge pulmonary trunk. This latter, which is limit-
ing factor for transvenous approach, could also in theory be
reduced by external lateral plication just before valve re-
placement. In addition, as available with bovine or porcine
xenograft, we anticipate that valves bigger than 22 mm could
be inserted without increasing dramatically the size of the
whole device, making possible a pulmonary valve replace-
ment by the hybrid technique in humans with no implant
size restriction.6 Finally, it could probably be performed
through a ministernotomy or left anterior lateral thoracot-
omy.11,12,15
Many valvular substitutes have been employed for valve
replacement, including homograft, pulmonary or aortic
xenograft with different kinds of preparation, bovine jugular1144 The Journal of Thoracic and Cardiovascular Svein, pericardial valve, tissue-engineered valve, among
others.15-17 Most of them have well-known limitations,
including thrombogenicity, susceptibility to infection, and
lack of growth potential. If human homograft valve is usu-
ally considered as the ‘‘gold standard,’’ its availability is
very restricted, especially in young patients. Actually,
none of the currently used heart valves meet the criteria
for an ideal valve replacement, and all have limited durabil-
ity.15 These limitations have led us to investigate others
strategies of valve preparation and implantation.7,9 In this
study, we focused on the possibility to adapt a new hybrid
approach to a biologic valve substitute with decreased
immunogenicity and better biocompatibility. We used a de-
cellularized porcine xenograft prepared in our laboratory by
a nonenzymatic decellularization technique as previously
described.7,8 This valve substitute remained satisfactory at
4-month follow-up after surgical implantation.9 In the pres-
ent study, we did not observe any calcification of this stented
decellularized valve. Furthermore, 4 months after implanta-
tion, the wall and leaflets remained thin and smooth and no
thrombosis was observed (Figure 4). The midterm hemody-
namic results were satisfactory with very low transvalvular
gradient, as compared with pulmonary homografts. Further
studies with long-term observation are needed to appreciate
the actual durability of this valve.
The main study limitation is probably the dissection of the
pulmonary trunk that will probably be more complex in
patients with repaired tetralogy of Fallot because of the post-
surgical adherences, which were not present in this experi-
mental work. This difficulty could possibly be overcome
by lateral plication of the main pulmonary trunk combined
with transmural sutures to secure valved stent positioning.
In conclusion, we report a hybrid approach using a decellu-
larized porcine valve mounted in a self-expandable stent to re-
place the pulmonary valve, without cardiopulmonary bypass.
This technique was found to be safe and effective, and the new
valved stent was able to function up to 4 months in the pulmo-
nary circulation. In addition, the hybrid approach allowed
reduction of the main pulmonary artery before implantation,
which has a major indication in patients with pulmonary in-
competence following repaired tetralogy of Fallot with the
transannular pulmonary patch technique. However, no data
are yet available on the long-term function of this decellular-
ized valved stent, and further long-term studies are mandatory
before considering human applications.
We thank Michel Pottier and Arnold Dive for their help in ani-
mal care.
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